Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 1 GROWTH Raising peak sales guidance for Cosentyx® to at least USD 7bn and EntrestoⓇ to at least USD 5bn CosentyxⓇ Sales evolution (USD bn) Illustrative Q4 Expected peak sales USD ≥ 7bn EntrestoⓇ Sales evolution (USD bn) Illustrative 9M Q4 ✓ Expected 9M 4.0 ✓ Expected 3.6 1.1 1.0 +18% 7.0+ 2.5 2.6 2.9 3.5 1.7 0.7 0.5 +41%1 2.6 1.8 1.2 2019 2020 2021 Peak 2019 2020 2021 Expected peak sales USD ≥ 5bn 5.0+ Peak Market growth, geographic expansion, LCM Market growth driven by increasing use of biologics Geographic expansion continues in China Market penetration, guidelines, geographic expansion Only 30% of HFrEF patients receive EntrestoⓇ ☐ Expansion to 10+ potential indications including HS, LP, LN, GCA 3+ potential formulations and dosing enhancements including i.v. ☐ Expanded label increases eligible US patient population to 5m patients Guidelines positioning EntrestoⓇ as first line therapy Significant opportunity in China and Japan, both including hypertension 1.9M vs PY 9 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation